youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
EXEL:NASDAQ
Exelixis Inc
$64.53
arrow_downward
-1.19%(-0.78) 1D
$64.53
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$65.15
High
$65.20
Low
$63.91
Mkt. cap
15.99B
Avg. vol.
2.28M
Volume
2.07M
P/E ratio
20.27
52-wk high
$65.50
52-wk low
$36.00
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
Open
$65.15
High
$65.20
Low
$63.91
Mkt. cap
15.99B
Avg. vol.
2.28M
Volume
2.07M
P/E ratio
20.27
52-wk high
$65.50
52-wk low
$36.00
EPS
$3.18
Beta
0.47
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
The Motley Fool
·
22 hours ago
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
FXEmpire
·
2 days ago
Exelixis Rises with Earnings on Tap
Yahoo Finance
·
3 days ago
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com
Analyst ratings
Based on 14 analysts giving stock ratings to EXEL in the past 3 months
Hold
Buy
4
Hold
9
Sell
1
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for EXEL in the last 3 months.
Highest
Current $64.53
$65.00 (+0.73%)
Average
$53.45 (-17.17%)
Lowest
$41.00 (-36.46%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Silvan Tuerkcan Citizens JMP | Buy | Maintained | $65.00 | +0.7% | 10/19/2026 |
Jason Gerberry Bank of America Securities | Sell | Maintained | $41.00 | -36.5% | 10/09/2026 |
Leonid Timashev RBC Capital | Hold | Maintained | $51.00 | -21% | 10/09/2026 |
Gregory Renza Truist Financial | Hold | Maintained | $54.00 | -16.3% | 10/07/2026 |
Stephen Willey Stifel Nicolaus | Hold | Maintained | - | - | 09/11/2026 |
Andy Hsieh William Blair | Buy | Reiterated | - | - | 09/11/2026 |
David Lebowitz BMO Capital | Hold | Maintained | $54.00 | -16.3% | 09/11/2026 |
Unknown Analyst Guggenheim | Hold | Maintained | - | - | 09/01/2026 |
Unknown Analyst BMO Capital | Hold | Maintained | $54.00 | -16.3% | 09/01/2026 |
Andrew Berens Leerink Partners | Hold | Downgraded | $52.00 | -19.4% | 08/06/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $64.00 | -0.8% | 08/05/2026 |
Derek Archila Wells Fargo | Hold | Reiterated | $50.00 | -22.5% | 08/06/2026 |
Eva Fortea Verdejo Wells Fargo | Hold | Reiterated | $50.00 | -22.5% | 08/06/2026 |
Sean Laaman Morgan Stanley | Hold | Maintained | $53.00 | -17.9% | 08/06/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $55.00 | -14.8% | 08/05/2026 |
Etzer Darout Barclays | Hold | Maintained | $49.00 | -24.1% | 08/06/2026 |
Unknown Analyst Wells Fargo | Hold | Maintained | $49.00 | -24.1% | 07/13/2026 |
Ashwani Verma UBS | Hold | Reiterated | $52.00 | -19.4% | 07/02/2026 |
Robert Burns H.C. Wainwright | Buy | Reiterated | $56.00 | -13.2% | 07/02/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $47.00 | -27.2% | 03/25/2026 |
Jay Olson Oppenheimer | Hold | Maintained | $36.00 | -44.2% | 03/03/2026 |
Unknown Analyst Stephens | Buy | Maintained | $60.00 | -7% | 02/11/2026 |
Michael Schmidt Guggenheim | Hold | Maintained | - | - | 02/10/2026 |
Next call in 4 days
Thu, Oct 29, 5:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $0.90
Revenue / Est. (USD)
- / 648.51M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 597.76M | 598.66M | 610.81M | 628.69M |
Cost of goods sold | 18.57M | 26.48M | 19.95M | 20.66M |
Cost of revenue | 18.57M | 26.48M | 19.95M | 20.66M |
Research and development expenses | 199.16M | 213.25M | 199.92M | 211.99M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 123.66M | 123.02M | 139.60M | 147.63M |
Operating expense | 322.82M | 336.27M | 339.52M | 359.62M |
Total operating expenses | 341.40M | 362.75M | 359.47M | 380.28M |
Operating income | 256.36M | 235.91M | 251.34M | 248.41M |
Other non operating income | -49.00K | 46.00K | 219.00K | 54.00K |
EBT including unusual items | 252.41M | 252.69M | 267.69M | 262.68M |
EBT excluding unusual items | 272.23M | 253.38M | 267.69M | 262.68M |
Income tax expense | 58.84M | 8.16M | 57.22M | 50.63M |
Effective tax rate | 23.31% | 3.23% | 21.38% | 19.27% |
Other operating expenses | - | - | - | - |
Net income | 193.58M | 244.53M | 210.47M | 212.05M |
Net profit margin | 32.38% | 40.85% | 34.46% | 33.73% |
Earnings per share | 0.78 | 0.94 | 0.87 | 0.91 |
Interest and investment income | 15.92M | 17.43M | 16.13M | 14.21M |
Interest expense | - | - | - | - |
Net interest expenses | 15.92M | 17.43M | 16.13M | 14.21M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 263.78M | 242.86M | 258.29M | 255.40M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1